The company plans to boost spending on research and development to $4.5 billion this year, up from $3.3 billion in 2022. Moderna MRNA, +2.00% provided the update in advance of the company’s presentation at the annual J.P. Morgan Healthcare Conference in San Francisco. CureVac said the shot was well tolerated, and that neutralizing antibodies were beginning at the lowest tested dose for younger adults. Ocugen announced positive results in a trial of its COVID vaccine Covaxin, which uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades. The U.S. leads the world with 101.2 million cases and 1,096,523 fatalities.

Source: Washington Post January 09, 2023 18:38 UTC